Immunotherapy in Melanoma: Role of TIGIT and LAG-3 on the antitumor immune microenvironment
Melanoma, is a malignant tumor arising from melanocytes. Given the ability of melanoma cells to inactivate lymphocytes, immunotherapy in melanoma has focused on using immune checkpoint inhibitors (ICIs) to counteract immune evasion. The lymphocyte activation gene 3 (LAG-3) and the inhibitory recepto...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | spa |
| Published: |
Universidad Pedagógica y Tecnológica de Colombia
2023
|
| Subjects: | |
| Online Access: | https://revistas.uptc.edu.co/index.php/ciencia_en_desarrollo/article/view/15041 |
| _version_ | 1801706356307132416 |
|---|---|
| author | Gaona Neira, Geidi Catherinne Salazar Prieto, Shanon Daniela Rondón Lagos, Sandra Milena |
| author_facet | Gaona Neira, Geidi Catherinne Salazar Prieto, Shanon Daniela Rondón Lagos, Sandra Milena |
| author_sort | Gaona Neira, Geidi Catherinne |
| collection | OJS |
| description | Melanoma, is a malignant tumor arising from melanocytes. Given the ability of melanoma cells to inactivate lymphocytes, immunotherapy in melanoma has focused on using immune checkpoint inhibitors (ICIs) to counteract immune evasion. The lymphocyte activation gene 3 (LAG-3) and the inhibitory receptor with Ig and ITIM domains (TIGIT) with its specific ligand Nectin-4 are emerging IPCs that are expressed in T cells. Overexpression of these immunological receptors is evident in melanoma, whereby different clinical trials have developed inhibitory molecules (as proven-drugs) that leading to the joint blockage of LAG-3 and TGIT/Nectin-4. Among these inhibitory molecules are PD-1/PD-L1, whose use, in addition to leading to the reduction of tumor proliferation and invasiveness, restores the activity of T cells and increases the antitumor immune response. However, the influence of LAG-3 and TIGIT/Nectin-4 on antitumor immune activity within the tumor microenvironment in melanoma remains unclear. This review describes the role of LAG-3 and TIGIT receptors in melanoma, the status of monotherapy and combination therapy targeting these immune receptors, the influence on the antitumor immune response, and the prospects for LAG-3 targeting immunotherapy. and TIGIT/Nectin-4 in melanoma. |
| format | Online |
| id | oai:oai.revistas.uptc.edu.co:article-15041 |
| institution | Revista Ciencia en Desarrollo |
| language | spa |
| publishDate | 2023 |
| publisher | Universidad Pedagógica y Tecnológica de Colombia |
| record_format | ojs |
| spelling | oai:oai.revistas.uptc.edu.co:article-150412024-05-10T00:51:44Z Immunotherapy in Melanoma: Role of TIGIT and LAG-3 on the antitumor immune microenvironment Inmunoterapia en Melanoma: Rol de TIGIT y LAG-3 en el microambiente inmune antitumoral Gaona Neira, Geidi Catherinne Salazar Prieto, Shanon Daniela Rondón Lagos, Sandra Milena Anticuerpos monoclonales Terapia antitumoral combinada punto de control inmunitario LAG-3 TIGIT células T Monoclonal antibodies T cells LAG-3 immune checkpoint combined antitumor therapy TIGIT Melanoma, is a malignant tumor arising from melanocytes. Given the ability of melanoma cells to inactivate lymphocytes, immunotherapy in melanoma has focused on using immune checkpoint inhibitors (ICIs) to counteract immune evasion. The lymphocyte activation gene 3 (LAG-3) and the inhibitory receptor with Ig and ITIM domains (TIGIT) with its specific ligand Nectin-4 are emerging IPCs that are expressed in T cells. Overexpression of these immunological receptors is evident in melanoma, whereby different clinical trials have developed inhibitory molecules (as proven-drugs) that leading to the joint blockage of LAG-3 and TGIT/Nectin-4. Among these inhibitory molecules are PD-1/PD-L1, whose use, in addition to leading to the reduction of tumor proliferation and invasiveness, restores the activity of T cells and increases the antitumor immune response. However, the influence of LAG-3 and TIGIT/Nectin-4 on antitumor immune activity within the tumor microenvironment in melanoma remains unclear. This review describes the role of LAG-3 and TIGIT receptors in melanoma, the status of monotherapy and combination therapy targeting these immune receptors, the influence on the antitumor immune response, and the prospects for LAG-3 targeting immunotherapy. and TIGIT/Nectin-4 in melanoma. El melanoma, es un tumor maligno que surge de los melanocitos. Dada la capacidad de células del melanoma de inactivar linfocitos, la inmunoterapia en melanoma se ha enfocado en emplear inhibidores de puntos de control inmunitario (CPI) para contrarrestar la evasión inmune. El gen de activación de linfocitos 3 (LAG-3) y el receptor inhibitorio con dominios Ig e ITIM (TIGIT) con su ligando específico Nectin-4, son CPIs emergentes que se expresan en células T. En melanoma se evidencia la sobreexpresión de estos receptores inmunitarios, por lo que diferentes ensayos clínicos han desarrollado moléculas inhibitorias que conducen al bloqueo conjunto de LAG-3 y TIGIT/Nectin-4. Dentro de estas moléculas inhibitorias se encuentran PD-1/PD-L1, cuyo uso además de conducir a la reducción de la proliferación y capacidad invasiva del tumor, restaura la actividad de las células T e incrementa la respuesta inmune antitumoral. Sin embargo, la influencia de LAG-3 y TIGIT/Nectin-4 en la actividad inmune antitumoral dentro del microambiente tumoral en melanoma aún no es clara. En esta revisión se describen el rol de los receptores LAG-3 y TIGIT en melanoma, el estado de la monoterapia y la terapia combinada dirigida a estos receptores inmunitarios, la influencia en la respuesta inmune antitumoral y las perspectivas de inmunoterapia dirigidas a LAG-3 y TIGIT/Nectin-4 en melanoma. Universidad Pedagógica y Tecnológica de Colombia 2023-07-19 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.uptc.edu.co/index.php/ciencia_en_desarrollo/article/view/15041 10.19053/01217488.v14.n2.2023.15041 Ciencia En Desarrollo; Vol. 14 No. 2 (2023): Vol 14, Núm.2 (2023): Julio-Diciembre; 13-29 Ciencia en Desarrollo; Vol. 14 Núm. 2 (2023): Vol 14, Núm.2 (2023): Julio-Diciembre; 13-29 2462-7658 0121-7488 spa https://revistas.uptc.edu.co/index.php/ciencia_en_desarrollo/article/view/15041/13669 |
| spellingShingle | Anticuerpos monoclonales Terapia antitumoral combinada punto de control inmunitario LAG-3 TIGIT células T Monoclonal antibodies T cells LAG-3 immune checkpoint combined antitumor therapy TIGIT Gaona Neira, Geidi Catherinne Salazar Prieto, Shanon Daniela Rondón Lagos, Sandra Milena Immunotherapy in Melanoma: Role of TIGIT and LAG-3 on the antitumor immune microenvironment |
| title | Immunotherapy in Melanoma: Role of TIGIT and LAG-3 on the antitumor immune microenvironment |
| title_alt | Inmunoterapia en Melanoma: Rol de TIGIT y LAG-3 en el microambiente inmune antitumoral |
| title_full | Immunotherapy in Melanoma: Role of TIGIT and LAG-3 on the antitumor immune microenvironment |
| title_fullStr | Immunotherapy in Melanoma: Role of TIGIT and LAG-3 on the antitumor immune microenvironment |
| title_full_unstemmed | Immunotherapy in Melanoma: Role of TIGIT and LAG-3 on the antitumor immune microenvironment |
| title_short | Immunotherapy in Melanoma: Role of TIGIT and LAG-3 on the antitumor immune microenvironment |
| title_sort | immunotherapy in melanoma role of tigit and lag 3 on the antitumor immune microenvironment |
| topic | Anticuerpos monoclonales Terapia antitumoral combinada punto de control inmunitario LAG-3 TIGIT células T Monoclonal antibodies T cells LAG-3 immune checkpoint combined antitumor therapy TIGIT |
| topic_facet | Anticuerpos monoclonales Terapia antitumoral combinada punto de control inmunitario LAG-3 TIGIT células T Monoclonal antibodies T cells LAG-3 immune checkpoint combined antitumor therapy TIGIT |
| url | https://revistas.uptc.edu.co/index.php/ciencia_en_desarrollo/article/view/15041 |
| work_keys_str_mv | AT gaonaneirageidicatherinne immunotherapyinmelanomaroleoftigitandlag3ontheantitumorimmunemicroenvironment AT salazarprietoshanondaniela immunotherapyinmelanomaroleoftigitandlag3ontheantitumorimmunemicroenvironment AT rondonlagossandramilena immunotherapyinmelanomaroleoftigitandlag3ontheantitumorimmunemicroenvironment AT gaonaneirageidicatherinne inmunoterapiaenmelanomaroldetigitylag3enelmicroambienteinmuneantitumoral AT salazarprietoshanondaniela inmunoterapiaenmelanomaroldetigitylag3enelmicroambienteinmuneantitumoral AT rondonlagossandramilena inmunoterapiaenmelanomaroldetigitylag3enelmicroambienteinmuneantitumoral |
